CRISPR Therapeutics AG (CRSP) Income from Continuing Operations (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Income from Continuing Operations of 122931000.0 for Q1 2026, up 24.23% sequentially from 162245000.0 in Q4 2025, and up 9.6% YoY from 112162381.98 in Q1 2025.
CRISPR Therapeutics AG (CRSP) Income from Continuing Operations (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Income from Continuing Operations for 12 years, with the latest figure at 122931000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 9.6% year-over-year to 122931000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 600166000.0 (down 3391.11% YoY) and the FY2025 annual result came in at 613211000.0, down 1728.93% from the prior year.
- Income from Continuing Operations advanced to 122931000.0 in Q1 2026 per CRSP's latest filing, from 162245000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 366586000.0 in Q4 2024 and troughed at 208549000.0 in Q2 2025.
- A 5-year average of 88366529.41 and a median of 116591000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 310.09% in 2024, then tumbled 144.26% in 2025.
- Over 5 years, Income from Continuing Operations stood at 110575000.0 in 2022, then surged by 180.84% to 89392000.0 in 2023, then soared by 310.09% to 366586000.0 in 2024, then slumped by 144.26% to 162245000.0 in 2025, then rose by 24.23% to 122931000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 122931000.0, 162245000.0, and 106441000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -91.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -91.19 Mn |
| Mar 31, 2026 | -122.93 Mn |
| Dec 31, 2025 | -162.25 Mn |
| Sep 30, 2025 | -106.44 Mn |
| Jun 30, 2025 | -208.55 Mn |
| Mar 31, 2025 | -135.99 Mn |
| Dec 31, 2024 | 366.59 Mn |
| Sep 30, 2024 | -85.94 Mn |
| Jun 30, 2024 | -126.42 Mn |
| Mar 31, 2024 | -116.59 Mn |
| Dec 31, 2023 | 89.39 Mn |
| Sep 30, 2023 | -112.14 Mn |
| Jun 30, 2023 | -77.74 Mn |
| Mar 31, 2023 | -53.07 Mn |
| Dec 31, 2022 | -110.58 Mn |
| Sep 30, 2022 | -174.55 Mn |
| Jun 30, 2022 | -185.82 Mn |
| Mar 31, 2022 | -179.22 Mn |
| Dec 31, 2021 | -141.25 Mn |
| Sep 30, 2021 | -127.15 Mn |